メンバー

スタッフ

English Information

まつやま ゆたか

松山 裕教授   

MATSUYAMA Yutaka

公共健康医学専攻 生物統計学分野

matuyama [at] epistat.m.u-tokyo.ac.jp

研究

・臨床試験の計画と解析
・理論疫学
・統計的因果推論
・欠測データの解析
・経時データ解析

経歴

1992.3 東京大学医学部保健学科卒業
1994.3 東京大学大学院医学系研究科 健康科学・看護学専攻 博士前期課程修了
1996.8 同専攻博士後期課程中途退学、東京大学医学部 健康科学・看護学科 疫学・生物統計学教室 助手
1997.4 東京大学大学院医学系研究科 健康科学・看護学専攻 生物統計学分野 助手(配置換)
1997.11 東京大学学位取得(保健学)
1999.8 ハーバード大学公衆衛生大学院 生物統計学講座 研究員
2000.8 京都大学大学院医学研究科 社会健康医学系専攻 医療統計学分野 助教授
2003.4 東京大学大学院医学系研究科 健康科学・看護学専攻 生物統計学分野 助教授
2007.4 東京大学大学院医学系研究科 公共健康医学専攻 生物統計学分野 准教授(配置換)
2013.4 東京大学大学院情報学環・学府 准教授(配置換)
2014.4 東京大学大学院医学系研究科 公共健康医学専攻 生物統計学分野 教授

担当講義

学部2年生

  • 生物統計学(A1:木3・4限)

学部3年生

  • 疫学(S1:月3・4限)
  • 生物統計学実習(S1:水3・4限)
  • 医学データ解析(A1:金1・2限)
  • 医学データ解析実習(A1:金3・4限)
  • 臨床・疫学研究の実例(A1:火3限)
  • 公共健康科学演習I(A2:木3・4限)

学部4年生

  • 応用数理(S2:火1・2限)
  • 理論疫学(A1:火3・4限)

公共健康医学専攻

  • 医学データの統計解析(S1:木3・4限)
  • 医学研究のデザイン(S2:火3・4限)

医学科M0

  •  統計学(A1:木3・4限)

  1. Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, Honda G, Matsumoto I, Wada K, Furuse J, Matsuyama Y, Unno M; Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP). Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 2019; 49(2): 190-194.
  2. Ikuta K, Hanashi H, Hirai K, Ota Y, Matsuyama Y, Shimura A, Terauchi M, Momoeda M. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study. Int J Hematol. 2019; 109(1): 41-49.
  3. Yokota I, Matsuyama Y. Dynamic prediction of repeated events data based on landmarking model: application to colorectal liver metastases data. BMC Med Res Methodol. 2019; 19(1): 31.
  4. Iwata A, Iwatsubo T, Ihara R, Suzuki K, Matsuyama Y, Tomita N, Arai H, Ishii K, Senda M, Ito K, Ikeuchi T, Kuwano R, Matsuda H; Alzheimer's Disease Neuroimaging Initiative; Japanese Alzheimer’s Disease Neuroimaging Initiative. Effects of sex, educational background, and chronic kidney disease grading on longitudinal cognitive and functional decline in patients in the Japanese Alzheimer's Disease Neuroimaging Initiative study. Alzheimers Dement 2018; 4: 765-774.
  5. Imamura K, Furukawa TA, Matsuyama Y, Shimazu A, Kuribayashi K, Kasai K, Kawakami N. Differences in the effect of internet-based cognitive behavioral therapy for improving nonclinical depressive symptoms among workers by time preference: Randomized controlled trial. J Med Internet Res. 2018; 10; 20(8):e10231.
  6. Yamaguchi K, Kamatari Y, Ono F, Shibata H, Fuse T, Elhelaly A, Fukuoka M, Kimura T, Hosokawa-Muto J, Ishikawa T, Tobiume M, Takeuchi Y, Matsuyama Y, Ishibashi D, Nishida N, Kuwata K. A designer molecular chaperone against transmissible spongiform encephalopathy slows down the progression of the disease in mice and macaques. Nature Biomed Eng. 2019; 3: 206–219.
  7. Takeuchi Y, Shinozaki T, Kumamaru H, Hiramatsu T, Matsuyama Y. Analyzing intent-to-treat and per-protocol effects on safety outcomes using a medical information database: An application to the risk assessment of antibiotic-induced liver injury. Expert Opin Drug Saf. 2018; 17(11): 1071-1079.
  8. Kashiwabara K, Matsuyama Y. Reasonable two-stage adaptive designs for single-arm phase II clinical trials. Pharm Stat 2018; 17(6): 770-780.
  9. Hagiwara Y, Fukuda M, Matsuyama Y. The number of events per confounder for valid estimation of risk difference using modified least-squares regression. Am J Epidemiol. 2018;187:2481-2490.
  10. Taniguchi Y, Kitamura A, Shinozaki T, Seino S, Yokoyama Y, Narita M, Amano H, Matsuyama Y, Fujiwara Y, Shinkai S. Trajectories of arterial stiffness and all-cause mortality among community-dwelling older Japanese. Geriatr Gerontol Int. 2018;18(7):1108-13,
  11. Taniguchi Y, Kitamura A, Nofuji Y, Ishizaki T, Seino S, Yokoyama Y, Shinozaki T, Murayama H, Mitsutake S, Amano H, Nishi M, Matsuyama Y, Fujiwara Y, Shinkai S. Association of trajectories of higher-level functional capacity with mortality and medical and long-term care costs among community-dwelling older Japanese. J Gerontol A Biol Sci Med Sci. 2018;74(2):211-218..
  12. Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N, Liver Cancer Study Group of Japan. Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analyzed with propensity score weighting. Liver Int. 2018;38:484-493.
  13. Takeuchi Y, Shinozaki T, Matsuyama Y. A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies. BMC Med Res Methodol. 2018; 18: 4.
  14. Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M, The Liver Cancer Study Group of Japan. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer 2017; 6(4): 325–336.
  15. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Kubo S, Sakamoto M, Nakashima O, Kumada T, Kokudo N; Liver Cancer Study Group of Japan. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. Hepatology. 2017;66(2):510-7.
  16. Tanaka S, Matsuyama Y, Ohashi Y. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial. Stat Med. 2017;36(19):2963-77.
  17. Notake T, Kobayashi A, Shinkawa H, Kawahara T, Shimizu A, Yokoyama T, Hasegawa K, Kokudo N, Matsuyama Y, Makuuchi M, Miyagawa SI. Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection. Int J Clin Oncol. 2017;22(4):715-25.
  18. Ueno M, Li CP, Ikeda M, Ishii H, Mizuno N, Yamaguchi T, Ioka T, Oh DY, Ichikawa W, Okusaka T, Matsuyama Y, Arai D, Chen LT, Park YS, Furuse J. A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo. Cancer Chemother Pharmacol. 2017;80(2):307-15.
  19. Mukai H, Hagiwara Y, Imi K, Isaka H, Watanabe K, Matsuyama Y for the SELECT BC Study Group. The impact of treatment preferences in second-line chemotherapy on the prognosis of HER2-negative metastatic breast cancer. Oncology. 2017;93:315-322.
  20. Shinozaki T, Mansournia MA, Matsuyama Y. On hazard ratio estimators by proportional hazards models in matched-pair cohort studies. Emerg Themes Epidemiol. 2017;14:6.
  21. Shinozaki T, Hagiwara Y, Matsuyama Y. Re. Biases in randomized trials: a conversation between trialists and epidemiologists (Letter). Epidemiology. 2017; 28(4): e40-e41.
  22. Toyoda H, Tada T, Johnson PJ, Izumi N, Kadoya M, Kaneko S, Kokudo N, Ku Y, Kubo S, Kumada T, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kudo M; Liver Cancer Study Group of Japan. Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. J Gastroenterol. 2017;52(10):1112-21.
  23. Kozuma K, Kashiwabara K, Shinozaki T, Kozuma K, Oba K, Matsuyama Y. Two-by-two cross-over study to evaluate agreement between versions of a quantitative coronary analysis system (QAngio XA). Int J Cardiovasc Imaging. 2017;33(6):779-787. doi: 10.1007/s10554-017-1068-4.
  24. Taniguchi Y, Kitamura A, Murayama H, Amano H, Shinozaki T, Yokota I, Seino S, Nofuji Y, Nishi M, Yokoyama Y, Matsuyama Y, Fujuwara Y, Shinkai S. Mini-Mental State Examination Score Trajectories and Incident Disabling Dementia Among Community-Dwelling Older Japanese. Geriatr Gerontol Int. 2017;17(11):1928-35.
  25. Taniguchi Y, Fujiwara Y, Murayama H, Yokota I, Matsuo E, Seino S , Nofuji Y, Nishi M, Matsuyama Y, Shinkai S. Prospective Study of Trajectories of Physical Performance and Mortality Among Community-Dwelling Older Japanese. J Gerontol A Biol Sci Med Sci. 2016; 71:1492-1499.
  26. Taniguchi Y, Kitamura A, Seino S, Murayama H, Amano H, Nofuji Y, Nishi M, Yokoyama Y, Shinozaki T, Yokota I, Matsuyama Y, Fujiwara Y, Shinkai S. Gait Performance Trajectories and Incident Disabling Dementia Among Community-Dwelling Older Japanese. J Am Med Dir Assoc. 2017;18(2):192.e13-192.e20.
  27. Hasegawa K, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M, Teruya M, Yoshimi F, Kawasaki S, Koyama H, Oba M, Takahashi M, Mizunuma N, Matsuyama Y, Watanabe T, Makuuchi M, Kokudo N. Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases: A randomized controlled trial. PLoS One. 2016; 11(9): e0162400.
  28. Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Matsui O, Matsuyama Y. Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2016; 46(5): 372-90.
  29. Moriya J, Matsuyama Y. Estimating treatment effect of high hemoglobin using the principal stratification approach. Jpn J Biometrics. 2016; 37: 7-22.
  30. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N; Liver Cancer Study Group of Japan. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol. 2016; 65(5): 938-943.
  31. Yoshida M, Matsuyama Y. Interim analysis based on the weighted log-rank test for delayed treatment effects under staggered patient entry. J Biopharm Stat. 2016; 26(5): 842-58.
  32. Kitahara H, Waseda K, Sakamoto K, Yamada R, Huang CC, Nakatani D, Sakata K, Kawarada O, Yock PG, Matsuyama Y, Yokoi H, Nakamura M, Muramatsu T, Nanto S, Fitzgerald PJ, Honda Y. Impact of attenuated-signal plaque observed by intravascular ultrasound on vessel response after drug-eluting stent implantation. Atherosclerosis. 2017; 259: 68-74.
  33. Zhu Y, Chen CY, Matsuyama Y, Ohashi Y, Franklin JM, Setoguchi S. Comparative validity of methods to select appropriate cutoff weight for probabilistic linkage without unique personal identifiers. Pharmacoepidemiol Drug Saf. 2016; 25(4): 444-52.
  34. Takahashi M, Hasegawa K, Oba M, Saiura A, Arita J, Sakamoto Y, Shinozaki E, Mizunuma N, Matsuyama Y, Kokudo N. Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases. Invest New Drugs. 2016; 34(4): 468-73.
  35. Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Survival benefit of locoregional treatment for hepatocellular carcinoma with advanced liver cirrhosis. Liver Cancer. 2016; 5(3): 175-189.
  36. Iijima R, Nakamura M, Matsuyama Y, Muramatsu T, Yokoi H, Hara H, Okada H, Ochiai M, Suwa S, Hozawa H, Kawai K, Awata M, Mukawa H, Fujita H, Nanto S; J-DESsERT. Effect of optimal medical therapy before procedures on outcomes in coronary patients treated with drug-eluting stents. Am J Cardiol. 2016; 118(6): 790-6.
  37. Kokudo T, Hasegawa K, Amikura K, Uldry E, Shirata C, Yamaguchi T, Arita J, Kaneko J, Akamatsu N, Sakamoto Y, Takahashi A, Sakamoto H, Makuuchi M, Matsuyama Y, Demartines N, Malagó M, Kokudo N, Halkic N. Assessment of preoperative liver function in patients with hepatocellular carcinoma - The albumin-indocyanine green evaluation (ALICE) grade. PLoS One. 2016; 11(7): e0159530.
  38. Ichida A, Hasegawa K, Takayama T, Kudo H, Sakamoto Y, Yamazaki S, Midorikawa Y, Higaki T, Matsuyama Y, Kokudo N. Randomized clinical trial comparing two vessel-sealing devices with crush clamping during liver transection. Br J Surg. 2016; 103(13): 1795-1803.
  39. Takao T, Suka M, Yanagisawa H, Matsuyama Y, Iwamoto Y. Predictive ability of visit-to-visit variability in HbA1c and systolic blood pressure for the development of microalbuminuria and retinopathy in people with type 2 diabetes. Diabetes Res Clin Pract. 2017; 128: 15-23.
  40. Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver Cancer. 2016; 5(3): 190-7.
  41. Nakamura M, Muramatsu T, Yokoi H, Okada H, Ochiai M, Suwa S, Hozawa H, Kawai K, Awata M, Mukawa H, Fujita H, Shiode N, Asano R, Tsukamoto Y, Yamada T, Yasumura Y, Ohira H, Miyamoto A, Takashima H, Ogawa T, Ito S, Matsuyama Y, Nanto S; J-DESsERT investigators. Three-year follow-up outcomes of SES and PES in a randomized controlled study stratified by the presence of diabetes mellitus: J-DEsSERT trial. International Journal of Cardiology 2016; 208: 4-12.
  42. Shindoh J, Makuuchi M, Matsuyama Y, Mise Y, Arita J, Sakamoto Y, Hasegawa K, Kokudo N. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. Journal of Hepatology 2016; 64(3): 594-600.
  43. Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Izumi N, Kadoya M, Kaneko S, Ku Y, Kudo M, Takayama T, Nakashima O; Liver Cancer Study Group of Japan. Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer 2016; 122(1): 61-70.
  44. Omichi K, Shindoh J, Yamamoto S, Matsuyama Y, Akamatsu N, Arita J, Kaneko J, Sakamoto Y, Hasegawa K, Kokudo N. Postoperative outcomes for patients with non-B non-C hepatocellular carcinoma: A subgroup analysis of patients with a history of hepatitis B infection. Annals of Surgical Oncology 2015; 22(Suppl 3): 1034-1040.
  45. TakaoT, Matsuyama Y, Suka M, Yanagisawa H, Iwamoto Y. The combined effect of visit-to-visit variability in HbA1c and systolic blood pressure on the incidence of cardiovascular events in patients with type 2 diabetes. BMJ Open Diabetes Res Care 2015 Nov 13;3(1):e000129.
  46. Kokudo T, Hasegawa K, Uldry E, Matsuyama Y, Kaneko J, Akamatsu N, Aoki T, Sakamoto Y, Demartines N, Sugawara Y, Kokudo N, Halkic N. A new formula for calculating standard liver volume for living donor liver transplantation without using body weight. Journal of Hepatology 2015; 63(4): 848-854.
  47. Zhu Y, Matsuyama Y, Ohashi Y, and Setoguchi S. When to conduct probabilistic linkage vs. deterministic linkage? : A simulation study. Journal of Biomedical Informatics 2015; 56: 80-86.
  48. Gotoda T, Ishikawa H, Ohnishi H, Sugano K, Kusano C, Yokoi C, Matsuyama Y, Moriyasu F. Randomized controlled trial comparing gastric cancer screening by gastrointestinal X-ray with serology for Helicobacter pylori and pepsinogens followed by gastrointestinal endoscopy. Gastric Cancer 2015; 18(3): 605-611.
  49. Ng CF, Matsuyama y, and Ohashi Y. Case-only method to estimate the relative incidence of adverse events for comparison of two treatments: Application in disseminated intravascular coagulation patients. Japanese Journal of Biometrics 2015; 36: 13-24.
  50. Takao T, Kimura K, Suka M, Yanagisawa H, Kikuchi M, Kawazu S, Matsuyama Y. Relationships between the risk of cardiovascular disease in type 2 diabetes patients and both visit-to-visit variability and time-to-effect differences in blood pressure. Journal of Diabetes and Its Complications 2015; 29(5): 699-706.
  51. Imamura K, Kawakami N, Furukawa TA, Matsuyama Y, Shimazu A, Kasai K. Effects of an internet-based cognitive behavioural therapy intervention on preventing major depressive episodes among workers: a protocol for a randomised controlled trial. BMJ Open 2015; 5(5): e007590.
  52. Nakamura M, Muramatsu T, Yokoi H, Okada H, Ochiai M, Suwa S, Hozawa H, Kawai K, Awata M, Mukawa H, Fujita H, Shiode N, Asano R, Tsukamoto Y, Yamada T, Yasumura Y, Ohira H, Miyamoto A, Takashima H, Ogawa T, Matsuyama Y, Nanto S; J-DESsERT investigators. Outcomes of the largest multi-center trial stratified by the presence of diabetes mellitus comparing sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in patients with coronary artery disease. The Japan drug-eluting stents evaluation: a randomized trial (J-DESsERT). Cardiovascular Intervention and Therapeutics 2015; 30(2): 103-114.
  53. Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, Kudo M, Kubo S, Takayama T, Tateishi R, Fukuda T, Matsui O, Matsuyama Y, Murakami T, Arii S, Okazaki M, Makuuchi M. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatology Research 2015; 45(2): 123-127.
  54. Kimura T, Deshpande GA, Urayama KY, Masuda K, Fukui T, Matsuyama Y. Association of weight gain since age 20 with non-alcoholic fatty liver disease in normal weight individuals. Journal of Gastroenterology and Hepatology 2015; 30(5): 909-917.
  55. Imamura K, Kawakami N, Furukawa TA, Matsuyama Y, Shimazu A, Umanodan R, Kawakami S, Kasai K. Effects of an internet-based cognitive behavioral therapy intervention on improving work engagement and other work-related outcomes: an analysis of secondary outcomes of a randomized controlled trial. Journal of Occupational and Environmental Medicine 2015; 57(5): 578-584.
  56. Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Takayama T, Kokudo N; Liver Cancer Study Group of Japan. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Annals of Surgery 2015; 261(3): 513-520.
  57. Shinozaki T, Matsuyama Y. Doubly robust estimation of standardized risk difference and ratio in the exposed population. Epidemiology. 2015;26(6):873-7.
  58. Taniguchi Y, Fujiwara Y, Nofuji Y, Nishi M, Murayama H, Seino S, Tajima R, Matsuyama Y, Shinkai S. Prospective study of arterial stiffness and subsequent cognitive decline among community-dwelling older Japanese. Journal of Epidemiology 2015; 25(9): 592-599.
  59. Kitai S, Kudo M, Izumi N, Kaneko S, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Kadoya M, Matsuyama Y, Matsunaga T. Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score and BCLC system) in 4,649 cases from a Japanese nationwide survey. Digestive diseases 2014; 32(6):717-724.
  60. Otsuka M, Yokoi H, Matsuyama Y, Hayashi Y, Shiode N, Masaoka Y, Okimoto T, Tamekiyo H, Kawase T, Yamane K, Kagawa Y, Nakamura M, Muramatsu T, Nanto S; J-DESsERT investigators. Comparison of sirolimus- and paclitaxel-eluting stents in patients with moderate renal insufficiency: results from the J-DESsERT trial. Cardiovascular Revascularization Medicine 2014; 15: 323-328.
  61. Taguri M, Matsuyama Y, Ohashi Y. Model selection criterion for causal parameters in structural mean models based on a quasi-likelihood. Biometrics 2014; 70(3): 721–730.
  62. Takao T, Matsuyama Y, Suka M, Yanagisawa H, Kikuchi M, Kawazu S. Time-to-effect relationships between systolic blood pressure and the risks of nephropathy and retinopathy in patients with type 2 diabetes. Journal of Diabetes and its Complications 2014; 28(5): 674-678.
  63. Takao T, Matsuyama Y, Yanagisawa H, Kikuchi M, Kawazu S. Association between HbA1c variability and mortality in patients with type 2 diabetes. Journal of Diabetes and Its Complications 2014; 28(4): 494-499.
  64. Kashiwabara K, Matsuyama Y, Ohashi Y. A Bayesian stopping rule for sequential monitoring of serious adverse events. Therapeutic Innovation and Regulatory Science 2014; 48: 444-452.
  65. Imamura K, Kawakami N, Furukawa TA, Matsuyama Y, Shimazu A, Umanodan R, Kawakami S, Kasai K. Effects of an Internet-based cognitive behavioral therapy (iCBT) program in Manga format on improving subthreshold depressive symptoms among healthy workers: a randomized controlled trial. PLoS One 2014; 9(5): e97167.
  66. Shinozaki T, Matsuyama Y, Ohashi Y. Estimation of controlled direct effects in time-varying treatments using structural nested mean models: application to a primary prevention trial for coronary events with pravastatin. Stat Med. 2014;33(18):3214-28.
  67. Takao T, Matsuyama Y, Yanagisawa H, Kikuchi M, Kawazu S. Visit-to-visit variability in systolic blood pressure predicts development and progression of diabetic nephropathy, but not retinopathy, in patients with type 2 diabetes. Journal of Diabetes and its Complications 2014; 28(2): 185-190
  68. Aramaki O, Takayama T, Higaki T, Nakayama H, Ohkubo T, Midorikawa Y, Moriguchi M, Matsuyama Y. Decreased blood loss reduces postoperative complications in resection for hepatocellular carcinoma. Journal of Hepato-biliary Pancreatic Sciences 2014; 21(8): 585-591.
  69. Oba M, Hasegawa K, Matsuyama Y, Shindoh J, Mise Y, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M, Kokudo N. Discrepancy between recurrence-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure. Annals of Surgical Oncology 2014; 21(6): 1817-1824.
  70. Naito S, Imamura H, Tukada A, Matsuyama Y, Yoshimoto J, Sugo H, Ishizaki Y, Kawasaki S. Postoperative recurrence pattern and prognosis of patients with hepatocellular carcinoma, with particular reference to the hepatitis viral infection status. Liver International 2014; 34(5): 802-813.
  71. Aoki T, Kokudo N, Matsuyama Y, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Makuuchi M; for the Liver Cancer Study Group of Japan. Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: An analysis of 1160 cases from a nationwide survey. Annals of Surgery 2014; 259(3): 532-542.
  72. Utsunomiya T, Shimada M, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact. Annals of Surgery 2014; 259(2): 336-345.
  73. Hasegawa K, Makuuchi M, Kokudo N, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y. Impact of histologically confirmed lymph node metastases on patient survival after surgical resection for hepatocellular carcinoma: Report of a Japanese nationwide survey. Annals of Surgery 2014; 259(1): 166-170.
  74. Kato H, Nakagami G, Iwahira Y, Otani R, Nagase T, Iizaka S, Tamai N, Matsuyama Y, Sanada H. Risk factors and risk scoring tool for infection during tissue expansion in tissue expander and implant breast reconstruction. The Breast Journal 2013; 19(6): 618-826.
  75. Fujita R, Iimuro S, Shinozaki T, Sakamaki K, Uemura Y, Takeuchi A, Matsuyama Y, Ohashi Y. Decreased duration of acute upper respiratory tract infections with daily intake of fermented milk: A multicenter, double-blinded, randomized comparative study in users of day care facilities for the elderly population. Am J Infect Control. 2013; 41(12): 1231-1235.
  76. Taguri M, Matsuyama Y. Comments on ‘An information criterion for marginal structural models’ by R. W. Platt, M. A. Brookhart, S. R. Cole, D. Westreich, and E. F. Schisterman. Statistics in Medicine 2013; 32: 3590-3591.
  77. Ohki T, Tateishi R, Akahane M, Mikami S, Sato M, Uchino K, Arano T, Enooku K, Kondo Y, Yamashiki N, Goto T, Shiina S, Yoshida H, Matsuyama Y, Omata M, Ohtomo K, Koike K. CT with hepatic arterioportography as a pretreatment examination for hepatocellular carcinoma patients: A randomized controlled trial. The American Journal of Gastroenterology 2013; 108(8): 1305-1313.
  78. Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y. Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey. Journal of Hepatology 2013; 58(4):724-729.
  79. Shindoh J, Hasegawa K, Matsuyama Y, Inoue Y, Ishizawa T, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M, Kokudo N. Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus. Journal of Clinical Oncology 2013; 31(6): 766-773.
  80. Seyama Y, Imamura H, Inagaki1 Y, Matsuyama Y, Tang W, Makuuchi M, Kokudo N. Intermittent clamping is superior to ischemic preconditioning and its effect is more marked with shorter clamping cycles in the rat liver. Journal of Gastroenterology 2013; 48(1): 115-124.
  81. Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Ichida T, Nakashima O, Matsui O, Izumi N, Ku Y, Kokudo N, Makuuchi M for the Liver Cancer Study Group of Japan. Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm. Liver International 2013; 33(5): 762-770.
  82. Shinozaki T, Matsuyama Y, Iimuro S, Umegaki H, Sakurai T, Araki A, Ohashi Y, Ito H, for the Japanese Elderly Diabetes Intervention Trial Research Group. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model. Geriatr Gerontol Int. 2012; 12 (Suppl. 1): S88-S102.
  83. Taguri M, Matsuyama Y, Ohashi Y, Harada A and Ueshima H. Doubly robust estimation of the generalized impact fraction. Biostatistics 2012; 13: 455-467.
  84. Takayasu K, Arii S, Kudo M, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Kokudo N, Makuuchi M. Superselective transarterial chemoembolization for hepatocellular carcinoma: Validation of treatment algorithm proposed by Japanese guidelines. Journal of Hepatology 2012; 56(4): 886-892.
  85. Isayama H, Yasuda I, Ryozawa S, Maguchi H, Igarashi Y, Matsuyama Y, Katanuma A, Hasebe O, Irisawa A, Itoi T, Mukai H, Arisaka Y, Okushima K, Uno K, Kida M, Tamada K. Results of a Japanese multicenter, randomized trial of endoscopic stenting for non-resectable pancreatic head cancer (JM-TEST): Covered wallstent versus doublelayer stent. Digestive Endoscopy 2011; 23(4): 310-315.
  86. Higashi T, Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y, Sobue T; the Liver Cancer Study Group of Japan. Demonstration of quality of care measurement using the Japanese liver cancer registry. Hepatology Research 2011; 41(12): 1208-1215.
  87. Aoki T, Imamura H, Matsuyama Y, Kishi Y, Kobayashi T, Sugawara Y, Makuuchi M and Kokudo N. Convergence process of volumetric liver regeneration after living-donor hepatectomy. Journal of Gastrointestinal Surgery 2011; 15:1594-1601.
  88. Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M; for the Liver Cancer Study Group of Japan. Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. British Journal of Surgery 2011; 98(4): 552-557.
  89. Araki Y, Matsuyama Y, Kobayashi Y, Toyokawa S, Inoue K, Suzuki S and Makimoto A. Secondary neoplasms after retinoblastoma treatment: Retrospective cohort study of 754 patients in Japan. Japanese Journal of Clinical Oncology 2011; 41(3): 373-379.
  90. Takeuchi A, Matsuyama Y, Ohashi Y, and Ueshima H. Monte Carlo sensitivity analysis for adjusting multiple-bias in the longitudinal cardiovascular study. Japanese Journal of Biometrics 2010; 31: 63-76.
  91. Taguri M, Matsuyama Y, Ohashi Y, Sone H, Yoshimura Y, and Yamada N. A hierarchical regression model for dietary data adjusting for covariates measurement error by regression calibration: An application to a large prospective study for diabetic complications. Japanese Journal of Biometrics 2010; 31: 49-62.
  92. Saito M, Iwata N, Kawakami N, Matsuyama Y, Ono Y, Nakane Y, Nakamura Y, Tachimori H, Uda H, Nakane H, Watanabe M, Naganuma Y, Furukawa TA, Hata Y, Kobayashi M, Miyake Y, Takeshima T, Kikkawa T; World Mental Health Japan 2002?2003 Collaborators. Evaluation of the DSM-IV and ICD-10 criteria for depressive disorders in a community population in Japan using item response theory. International Journal of Methods in Psychiatric Research 2010; 19: 211-222.
  93. Ikai I, Kudo M, Arii S, Omata M, Kojiro M, Sakamoto M, Takayasu K, Hayashi N, Makuuchi M, Matsuyama Y and Monden M. Report of the 18th follow-up survey of primary liver cancer in Japan. Hepatology Research 2010 40; 1043-1059.
  94. Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, Shums Z, Aoki T, Hasegawa K, Beck Y, Sugawara Y, Kokudo N. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. Journal of Gastroenterology 2010; 45: 1272-1282.
  95. Matsuyama Y. A comparison of the results of intent-to-treat, per-protocol, and g-estimation in the presence of non-random treatment changes in a time-to-event non-inferiority trial. Statistics in Medicine 2010; 29: 2107-2116.
  96. Takao T, Idea T, Yanagisawa H, Kikuchi M, Kawazu S, Matsuyama Y. The effect of fasting plasma glucose variability on the risk of retinopathy in type 2 diabetic patients: retrospective long-term follow-up. Diabetes Research and Clinical Practice 2010; 89: 296-302.
  97. Shimizu F, Taguri M, Harada Y, Matsuyama Y, Sase K, Fujime M. Impact of dry ejaculation caused by highly selective alpha1A-blocker: Randomized, double-blind, placebo-controlled crossover pilot study in healthy volunteer men. Journal of Sexual Medicine 2010; 7(3): 1277-1283.
  98. Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, and Makuuchi M for the Liver Cancer Study Group of Japan. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: Propensity score analysis. American Journal of Roentgenology 2010; 194: 830-837.
  99. Yasunaga H, Matsuyama Y, Ohe K; Japan Surgical Society. Effects of hospital and surgeon volumes on operating times, postoperative complications, and length of stay following laparoscopic colectomy. Surgery Today 2009; 39(11): 955-961.
  100. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, Shimada M, Kanemitsu K. A randomized phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. British Journal of Cancer 2009; 101: 908-915.
  101. Yasunaga H, Nishii O, Hirai Y, Ochiai K, Matsuyama Y, and Ohe K. Impact of surgeon and hospital volumes on short-term postoperative complications after radical hysterectomy for cervical cancer. The Journal of Obstetrics and Gynaecology Research 2009; 35: 699-705.
  102. Yamamoto K, Imamura H, Matsuyama Y, Hasegawa K, Beck Y, Sugawara Y, Makuuchi M and Kokudo N. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Annals of Surgical Oncology 2009; 16: 2795-2804.
  103. Yasunaga H, Matsuyama Y, Ohe K; Japan Surgical Society. Volume-outcome relationship in rectal cancer surgery: a new perspective. Surgery Today 2009; 39(8): 663-668.
  104. Yasunaga H, Matsuyama Y, Ohe K; Japan Surgical Society. Effects of hospital and surgeon case-volumes on postoperative complications and length of stay after esophagectomy in Japan. Surgery Today 2009; 39(7): 566-571.
  105. Yasunaga H, Tsuchiya K, Matsuyama Y, Ohe K. Analysis of factors affecting operating time, postoperative complications, and length of stay for total knee arthroplasty: nationwide web-based survey. Journal of Orthopaedic Science 2009; 14(1): 10-16.
  106. Yasunaga H, Tsuchiya K, Matsuyama Y, Ohe K. High-volume surgeons in regard to reductions in operating time, blood loss, and postoperative complications for total hip arthroplasty. Journal of Orthopaedic Science 2009; 14(1): 3-9.
  107. Yoshida S, Matsuyama Y, Ohashi Y, and Ueshima H. A Poisson mixed effects model for investigating the exposure-by-cohort interaction: A Gibbs sampling approach. Japanese Journal of Biometrics 2008; 29: 61-74.
  108. Yasunaga H, Matsuyama Y, Ohe K for the Japan Neurosurgical Society. Risk-adjusted analyses of the effects of hospital and surgeon volumes on postoperative complications and the modified Rankin scale after clipping of unruptured intracranial aneurysms in Japan. Neurologia Medico-Chirurgica 2008; 48: 531-538.
  109. Matsuyama Y and Yamaguchi T. Estimation of the marginal survival time in the presence of dependent competing risks using inverse probability of censoring widthed (IPCW) methods. /Pharmaceutical Statistics/ 2008; 7: 202-214.
  110. Yasunaga H, Yanaihara H, Fuji K, Matsuyama Y, Deguchi N, and Ohe K. Influence of hospital and surgeon volumes on operative time, blood loss, and perioperative complications in radical nephrectomy. /International Journal of Urology/ 2008; 15: 688-693.
  111. Hasegawa K, Makuuchi M, Takayama T, Kokudo N, Arii S, Okazaki M, Okita K, Omata M, Kudo M, Kojiro M, Nakanuma Y, Takayasu K, Monden M, Matsuyama Y, and Ikai I for the Liver Cancer Study Group of Japan. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: A preliminary report of the Japanese nationwide survey. /Journal of Hepatology/ 2008; 49: 589-594.
  112. Uemura K, Matsuyama Y, and Ohashi Y. A modified conditional power approach for increasing the sample size based on an interim estimate of treatment difference. Japanese Journal of Biometrics 2008; 29: 19-34.
  113. Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, and Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatology International 2008; 2: 17-30.
  114. Hasegawa K, Imamura H, Ijichi M, Matsuyama Y, Sano K, Sugawara Y, Kokudo N, and Makuuchi M. Inclusion of tumor markers improves thecorrelation of the Milan criteria with vascular invasion and tumor cell differentiation in patients with hepatocellular carcinoma undergoing liver resection. /Journal of Gastrointestinal Surgery/ 2008; 12(5):858-866.
  115. Eguchi S, Kanematsu T, Arii S, Okazaki M, Okita K, Omata M, Ikai I, Kudo M, Kojiro M, Makuuchi M, Monden M, Matsuyama Y, Nakanuma Y, Takayasu K for the Liver Cancer Study Group of Japan. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 2008; 143: 469-475.
  116. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M, Saida Y, Takayama T, and Yamaoka Y. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatology Research 2008 38: 37-51.
  117. Tanaka Y, Matsuyama Y, and Ohashi Y. for the MEGA Study Group. Estimation of treatment effect adjusting for treatment changes using the intensity score method: an application to a large primary prevention study for coronary events (MEGA study). Statistics in Medicine 2008; 27:1718-1733.
  118. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M, and Kudo M. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatology Research 2007; 37(9):676-691.
  119. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, and Makuuchi M. Staging of hepatocellular carcinoma: Assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Annals of Surgery 2007; 245(6):909-922.
  120. Yoshida M, Matsuyama Y, and Ohashi Y for the MEGA Study Group. Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study). Clinical Trials 2007; 4: 318-328.
  121. Tanaka S, Matsuyama Y, Shiraki M, Ohashi Y. Estimating the effect of time-varying treatments: Incidence of fractures among postmenopausal Japanese women. Epidemiology 2007; 18: 529-536.
  122. Nakagami G, Sanada H, Konya C, Kitagawa A, Tadaka E, and Matsuyama Y. Evaluation of a new pressure ulcer preventive dressing containing ceramide 2 with low frictional outer layer. Journal of Advanced Nursing 2007; 59(5): 520-529.
  123. Shimizu F, Matsuyama Y, Tominaga T, Ohashi Y, and Fujime M. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy. Urologia Internationalis 2007; 79: 356-360.
  124. Shimizu F, Tanaka S, Matsuyama Y, Tominaga T, Ohashi Y, and Fujime M. Efficiency of ultrasensitive prostate-specific antigen assay in diagnosing biochemical failure after radical prostatectomy. Japanese Journal of Clinical Oncology 2007; 37: 446-451.
  125. Minagawa, M, Yamamoto J, Kosuge T, Matsuyama Y, Miyagawa S, and Makuuchi M. Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: Development and Validation. Archives of Surgery 2007; 142(3):269-276.
  126. Matsuyama Y and Morita S. Estimation of the average causal effect among subgroups defined by post-treatment variables. Clinical Trials 2006; 3: 1-9.
  127. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, and Yamaoka Y for Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131(2): 461-469.
  128. Ikai I, Takayasu K, Omata M, Okita K, Nakanuma Y, Matsuyama Y, Makuuchi M, Kojiro M, Ichida T, Arii S., and Yamaoka Y for the Liver Cancer Study Group of Japan. A modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma. Journal of Gastroenterology 2006; 41(9): 884-892.
  129. Doi K, Matsuyama Y, and Ohashi Y. Analysis of quality of life data with death and drop-out in advanced non-small-cell lung cancer patients. Japanese Journal of Biometrics 2006; 27(1): 17-33.
  130. Sakamoto K, Matsuyama Y, and Ohashi Y. Sensitivity analysis of publication bias in meta-analysis: A Bayesian approach. Japanese Journal of Biometrics 2006; 27(2): 109-119.
  131. Hasegawa K, Takayama T, Ijichi M, Matsuyama Y, Imamura H, Sano K, Sugawara Y, Kokudo N, and Makuuchi M. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: A randomized trial. Hepatology 2006; 44(4): 891-895.
  132. Chiba Y, Matsuyama Y, Sato T, and Yoshimura I. A simulation study for a linear measurement error model when error variances vary between measurements. Journal of Agricultural, Biological, and Environmental Statistics. 2005; 10: 118-130.
  133. Mizuno S, Yamaguchi T, Fukushima A, Matsuyama Y, and Ohashi Y. Overlap coefficient for assessing the similarity of pharmacokinetic data between ethnically different populations. Clinical Trials 2005; 2: 174-181.
  134. Aoki T, Imamura H, Kaneko J, Sakamoto Y, Matsuyama Y, Kokudo N, Sugawara Y, Makuuchi M. Intraoperative direct measurement of hepatic arterial buffer response in patients with or without cirrhosis. Liver Transplantation 2005; 11(6): 684-691.
  135. Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, Sano K, Sugawara Y, Takayama T, and Makuuchi M. Prognostic impact of anatomical resection for hepatocellular carcinoma. Annals of Surgery 2005; 242(2): 252-259.
  136. Ikai I, Arii S, Ichida T, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, and Yamaoka Y. Report of the 16th follow-up survey of primary liver cancer. Hepatology Research 2005; 32: 163-172.
  137. Matsuyama Y. Analysis of longitudinal studies with death and drop-out. DIA 11th Annual Workshop in Japan for Biostatistics 26-27, August, 2004, Tokyo, Japan
  138. Matsuyama Y, Yamaguchi T, Hashimoto S, Kawado M, Ichikawa S, Umeda T, and Kihara M. Epidemiological characteristics of HIV and AIDS in Japan based on HIV/AIDS surveillance data: An international comparison. The Journal of AIDS Research. 2004; 6: 184-193.
  139. Ishizaki T, Kai I, Kobayashi Y, Matsuyama Y, and Imanaka Y. The effect of aging on functional decline among older Japanese living in a community: a 5-year longitudinal data analysis. Aging Clinical and Experimental Research 2004; 16: 233-239.
  140. Teramukai S, Matsuyama Y, Mizuno S, and Sakamoto J. Individual patient-level and study-level meta-analysis for investigating modifiers of treatment effect. Japanese Journal of Clinical Oncology 2004; 34: 717-721.
  141. Ikai I, Arii S, Kojiro M, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Nakanuma Y, Okita K, Omata M, Takayasu K, and Yamaoka Y. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004; 15; 101(4): 796-802.
  142. Matsuyama Y. Editorial comments: Comparison of outcomes of three different surgical techniques performed for stress urinary incontinence. International Journal of Urology. 2003; 10: 131.
  143. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, and Makuuchi M. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. Journal of Hepatology. 2003; 38: 200-207.
  144. Sato T and Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology. 2003; 14(6): 680-686.
  145. Ogihara N, Ebihara S, Kawamura W, Okamoto M, Sakai T, Takiguchi K, Morita T, Uchida R, Matsuyama Y, Hayashi Y, Arakawa Y and Kikuchi, M. Characterization of the portal signal in a non-steady hyperglycemic state in conscious dogs. American Journal of Physiology - Endoclinology and Metabolism. 2003; 284: 148-155.
  146. Kawado M, Hinotsu S, Matsuyama Y, Yamaguchi T, Hashimoto S, and Ohashi Y. A comparison of error detection rates between the reading aloud method and the double data entry method. Controlled Clinical Trials 2003; 24: 560-569.
  147. Matsuyama Y. Sensitivity analysis for the estimation of rates of change with non-ignorable drop-out: An application to a randomized clinical trial of the vitamin D3. Statistics in Medicine. 2003; 22. 811-827.
  148. Yamaguchi T, Ohashi Y, and Matsuyama Y. Proportional hazards models with random effects to examine centre effects in multicentre cancer clinical trials. Statistical Methods in Medical Research. 2002; 11: 221-236.
  149. Miyagawa Y, Imamura H, Soeda J, Matsunaga K, Mochida S, Fujiwara K, Matsuyama Y, and Kawasaki S. Fate of hepatocyte and sinusoidal lining cell function and kinetics after extended cold preservation and transplantation of the rat liver. Liver Transplantation. 2002; 8(4): 370-381.
  150. Imamura H, Takayama T, Sugawara Y, Kokudo N, Aoki T, Kaneko J, Matsuyama Y, Sano K, Maema A, and Makuuchi M. Pringle's maneuver in living donors. Lancet. 2002; 360: 2049-2050.
  151. Matsuyama Y. Correcting for non-compliance of repeated binary outcomes in randomized clinical trials: Randomized analysis approach. Statistics in Medicine. 2002; 21. 657-687.
  152. Imamura H, Matsuyama Y, Shimada R, Kubota M, Nakayama A, Kobayashi A, Kitamura H, Ikegami T, Miyagawa SI, Kawasaki S. A study of factors influencing prognosis after resection of hepatic metastases from colorectal and gastric carcinoma. American Journal of Gastroenterology. 2001; 96(11):3178-3184.
  153. Kobayashi A, Imamura H, Isobe M, Matsuyama Y, Soeda J, Matsunaga K, and Kawasaki S. Mac-1 (CD11b/CD18) and intercellular adhesion molecule-1 in ischemia-reperfusion injury of rat liver. American Journal of Physiology Gastrointest Liver Physiol. 2001; 281(2):G577-85.
  154. Nakayama A, Imamura H, Matsuyama Y, Kitamura H, Miwa S, Kobayashi A, Miyagawa S, and Kawasaki S. Value of lipiodol computed tomography and digital subtraction angiography in the era of helical biphasic computed tomography as preoperative assessment of hepatocellular carcinoma. Annals of surgery. 2001; 234:56-62.
  155. Toyoda I, Matsuyama Y, and Ohashi Y. Estimation and comparison of rates of change in repeated-measures studies with planned dropout. Controlled Clinical Trials. 2001; 22(6):620-638.
  156. Matsuyama Y, Tominaga T, Nomura Y, Koyama H, Miura S, Takashima S, Sano M, Mitsuyama S, Ueo H, and Ohashi Y. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. Annals of Oncology. 2000; 11(12): 1537-1543.
  157. Hashimoto S, Matsumoto T, Nagai M, Matsuyama Y, Nakamura Y, Umeda T, Kamakura M, Ichikawa S, Kimura S, Fukutomi K, and Kihara M. Delays and continuation of hospital visits among HIV-infected persons and AIDS cases in Japan. Journal of Epidemiology. 2000; 10(1): 65-70.
  158. Imamura H, Shimada R, Kubota M, Matsuyama Y, Nakayama A, Miyagawa S, Makuuchi M, and Kawasaki S. Preoperative portal vein embolization: An audit of 84 patients. Hepatology. 1999; 29: 1099-1105.
  159. Imamura H, Matsuyama Y, Miyagawa Y, Ishida K, Shimada R, Miyagawa S, Makuuchi M, and Kawasaki S. Prognostic significance of anatomical resection and des-γ-carboxy prothrombin in patients with hepatocellular carcinoma. British Journal of Surgery. 1999; 86(8): 1032-1038.
  160. Matsuyama Y, Hashimoto S, Ichikawa S, Nakamura Y, Kidokoro T, Umeda T, Kamakura M, Kimura S, Fukutomi K, Ikeda C, and Kihara M. Trends in HIV and AIDS based on HIV/AIDS surveillance data in Japan. International Journal of Epidemiology. 1999; 28: 1149-1155.
  161. Sakamoto J, Matsuyama Y, and Ohashi Y. An analysis of the institutional effects in a multicenter cancer clinical trial- Is it also plausible from the clnicians’ point of view-. Japanese Journal of Clinical Oncology. 1999; 29(8): 403-405.
  162. Matsuyama Y, Sakamoto J, and Ohashi Y. A Bayesian hierarchical survival model for the institutional effects in a multicenter cancer clinical trial. Statistics in Medicine. 1998; 17: 1893-1908.
  163. Matsuyama Y and Ohashi Y. Mixed models for bivariate response repeated measures data using Gibbs sampling. Statistics in Medicine. 1997; 16: 1587-1601.
  164. Matsuyama Y, Ohashi Y, Uchino H, Takaku F, Otsuka Y, and Suzuki A. Vesnarinon-induced WBC disorders in Japan. Pharmacoepidemiology and Drug Safety. 1996; 5: 87-93.
  165. Kikuchi M and Matsuyama Y. Cumulative effect of hyperglycemia on the advent of microangiopathies. Excerpta Medica ICS. 1994; 1057: 417-421.

論文(和文)

  1. 松山 裕.ランダム化臨床試験の実践的方法論.脊椎外科.2018; 32(1): 29-33.
  2. 上原里程, 柏原康佑, 松山裕, 村上義孝. 受療行動調査を用いた自宅療養の希望およびその見通しと医療施設特性との関連分析. 厚生の指標 2016; 63(7): 1–6.
  3. 松山 裕.Intention-to-treat解析,Full Analysis Set, Per Protocol Set.内分泌・糖尿病・代謝内科.2017; 45(2): 142-146.
  4. 柏原康佑,松山 裕,上原里程,村上義孝.受療行動調査の患者不満足に医療施設特性が及ぼす影響.日本公衆衛生雑誌 2015; 62(10): 587-595.
  5. 後藤 昌也,荒川 義弘,上田 哲也,里中 弘志,松山  裕,大橋 靖雄.東京大学医学部附属病院における研究者主導臨床試験プロトコルの質評価.薬理と治療.2014; 42 suppl 2: s135-s147.
  6. 松山 裕.医学研究における統計解析手法の選択.画像診断.2014; 34(12): 1383-1389.
  7. 松 山 裕.欠側データの取り扱い.Diabetes Frontier 2014; 25(4): 2014-2018.
  8. 松山 裕.生存時間解析.心身医学.2013; 53: 1031-1038.
  9. 松山 裕.連続データの解析.心身医学.2013; 53: 953-957.
  10. 松山 裕.書評:統計的因果推論-モデル・推論・推測-.統計.2013; 64: 82-83.
  11. 松山 裕.カテゴリカルデータの解析.心身医学.2013; 53: 874-879.
  12. 松山 裕.研究デザインと統計解析手法の選択.心身医学.2013; 53: 764-770.
  13. 松山 裕.統計的仮説検定と効果の推定.心身医学.2013; 53: 687-693.
  14. 松山 裕.データの要約:要約統計量と分布の視覚化.心身医学.2013; 53: 436-441.
  15. 松山 裕.欠測データにどのように対応するか.医学のあゆみ.2013; 244: 1258-1262.
  16. 前田晋至,原 直彦,竹内文乃,松山 裕.「患者の求める医療連携」を推進・形成させる潜在的な因子の特定.日本プライマリ・ケア連合学会 誌.2012; 35: 291-298.
  17. 篠崎智大,松山 裕.混合モデル(mixed models). 動脈硬化予防.2012; 11(2): 93-95.
  18. 佐藤俊哉,松山裕.交絡という不思議な現象と交絡を取り除く解析- 標準化と周辺構造モデル -.計量生物学.2011; 32:S35-S49.
  19. 松山 裕.ベイズ統計学とは.臨床評価.2010; 38: 269-279.
  20. 工藤正俊, 有井滋樹, 猪飼伊和夫, 小俣政男, 神代正道, 坂元亨宇,高安 賢一, 林紀夫,幕内雅敏, 松山 裕, 門田守人, 日本肝癌研究会追跡調査委員 会.第18回全国原発性肝癌追跡調査報告 (2004~2005).肝臓. 2010; 51(8): 460-484.
  21. 松山 裕.臨床研究における生物統計学の役割.日本耳鼻咽喉科学会会報.2010; 113: 1-8.
  22. 松山 裕.ベイズ統計学の基本.遥か 2009; *5*; 37-45.
  23. 松山 裕.臨床統計学の基礎知識./Oncology Nursing/ 2009; 3: 9-11.
  24. 田中夕香理,松山 裕.ランダム化後のイベントに対するprincipal stratificationに基づく調整解析. 臨床研究・生物統計研究会誌 2008; 28: 51-55.
  25. 松山 裕.パワー不足はサンプルサイズで調節せよ.外科 2008; 70; 1109-1114.
  26. 松山 裕,田中夕香理,吉田瑞樹,大橋靖雄.MEGA Studyにおける同意撤回・治療変更の影響分析 -全期間と5年間の結果の相違は何故生じたか?-. /Progress in Medicine/ 2008; 28: 1959-1967.
  27. 田林晄一,高本眞一,平田 哲,中田精三,波利井清紀,樫村暢一,磯部 陽,炭山嘉伸,北川哲也,兼松隆之,杉浦伸一,山口俊晴,國土典宏,松山 裕,小柳 仁,出月康夫.心臓血管手術時に使用する特殊縫合糸使用実態の多施設調査.日本外科学会雑誌.2007; 108(3): 153.
  28. 國土典宏,兼松隆之,炭山嘉伸,中田精三,島田光生,樫村暢一,磯部陽,平田哲,山口俊晴,松山 裕,杉浦伸一,出月康夫.肝臓手術と膵臓手術における特殊縫合糸使用実態に関する多施設調査-経済的側面からの考察-.日本臨床外科学雑誌. 2007; 68(5): 1077-1081.
  29. 栗田昌和,波利井清紀,松山 裕,出月康夫.形成外科領域における特殊縫合糸の使用実態調査.日本形成外科学会誌.2007; 27(5): 353-356.
  30. 工藤正俊, 有井滋樹, 猪飼伊和夫, 岡崎正敏, 沖田極, 小俣政男, 神代正道, 高安賢一, 中沼安二, 幕内雅敏, 松山 裕, 門田守人, 日本肝癌研究会追跡調査委員会.第17回全国原発性肝癌追跡調査報告(2002~2003).肝臓. 2007; 48(3): 117-140.
  31. 倉橋一成,伊藤陽一,松山 裕,大橋靖雄,西尾和人.cDNAマクロアレイデータ解析における正規化手法の性能評価.日本統計学会誌.2007.36(2).147-63.
  32. 山岡義生, 猪飼伊和夫, 有井滋樹, 市田隆文, 沖田極, 小俣政男, 神代正道, 高安賢一, 中沼安二, 幕内雅敏, 松山 裕.第16回全国原発性肝癌追跡調査報告(2000~2001).肝臓.2005; 46(4): 234-254.
  33. 松山 裕.医学研究のデザイン概論1-ランダム化比較試験-.Surgery Frontier 2005; 12(2): 80-84.
  34. 松山 裕.医学研究のデザイン概論2-疫学研究-.Surgery Frontier 2005; 12(2): 85-90.
  35. 松山 裕.統計的仮説検定と治療効果の推定.Surgery Frontier 2005; 12(2): 91-96.
  36. 松山 裕.サンプルサイズの設計.Surgery Frontier 2005; 12(2): 97-101.
  37. 松山 裕,大庭幸治.統計解析の実際.Surgery Frontier 2004; 11(4): 412-419.
  38. 松山 裕.経時観察研究における欠測データの解析.計量生物学.2004; 25: 89-116.
  39. 川戸美由紀,橋本修二,山口拓洋,松山 裕,中村好一,木村博和,市川誠一,木原正博,白阪琢磨.エイズ拠点病院におけるHIV/AIDSの受療者数の推移.日本エイズ学会誌.2004; 6: 31-35.
  40. 松山 裕.コントロール(対照群)の考え方.Surgery Frontier 2004; 11: 76-80.
  41. 松山 裕.生物統計学の基礎的考え方.Surgery Frontier 2003; 10: 415-422.
  42. 手良向聡,松山 裕.ベイズ流階層モデルを用いたメタアナリシス.臨床研究・生物統計研究会誌.2003; 23: 83-88.
  43. 嘉田晃子,松山 裕,佐藤俊哉.中止・脱落の理由を考慮したIPCW法による臨床試験データの解析.計量生物学.2002; 23(2): 81-91.
  44. 小川幸男,松山 裕,佐藤俊哉.欠測が中間変数に依存する場合のmultiple imputationによる解析と欠測のある対象者を除いた解析のシミュレーションによる比較.計量生物学.2002; 23(2): 67-80.
  45. 山口拓洋,橋本修二,川戸美由紀,中村好一,木村博和,市川誠一,松山 裕,木原正博,白阪琢磨.エイズ治療の拠点病院におけるHIV/AIDSの受療者数.日本エイズ学会誌.2002; 4(3): 91-95.
  46. 橋本修二,福富和夫,山口拓洋,松山 裕,中村好一,木村博和,市川誠一,木原正博.HIV感染者数とAIDS患者数のシステム分析による中長期展望の試み.日本エイズ学会誌.2002; 4: 8-16.
  47. 松山 裕.糖尿病治療評価のための研究計画のデザインと統計解析法.Pharma Medica. 2001; 19(6): 51-56.
  48. 松山 裕,佐藤俊哉.ゆがんだ因果をときほぐす.分子がん治療.2001; 2(2): 141-145.
  49. 佐藤俊哉,松山 裕.臨床研究のデザイン:観察的研究.分子がん治療.2001; 2(1): 61-65.
  50. 松山 裕,佐藤俊哉.臨床研究のデザイン:ランダム化臨床試験.分子がん治療.2000; 1(2): 163-168.
  51. 佐藤俊哉,松山 裕.医学統計になぜ生物統計が必要か.分子がん治療.2000; 1(1): 70-75.
  52. 中村好一,松山 裕,城所敏英,梅田珠実,岡慎一,木村博和,鎌倉光宏,市川誠一,橋本修二,福富和夫,木村哲,木原正博. デルファイ法による調査結果からみたHIV感染/AIDS疫学像.日本エイズ学会誌.2000; 2(2): 127-133.
  53. 橋本修二,福富和夫,市川誠一,松山 裕,中村好一,木原正博.HIV感染者数とAIDS患者数の将来予測.日本エイズ学会誌.2000; 2(1): 35-42.
  54. 松山 裕,橋本修二,市川誠一,中村好一,城所敏英,福富和夫,木原正博.エイズサーベイランス報告に基づく死亡報告数の推移とその検討.日本エイズ学会誌.2000; 2(1): 30-34.
  55. 大木いずみ,橋本修二,市川誠一,鎌倉光宏,城所敏英,木原正博,木村博和,木村哲,松山 裕,岡慎一,梅田珠実,福富和夫,中村好一.人口動態統計からみたエイズに関する死亡数の動向.厚生の指標.1999; 46(8): 26-33.
  56. 船木真理,葛谷信明,松山 裕,奥田保子,荻原健英,菊池方利:動脈硬化性プラーク形成に関わる食事因子の検討-新たな促進因子としての鉄摂取量-.糖尿病 42:880,1999
  57. 清信浩一,長内麻子,東綾実,神田善姫,斎藤洋一,松村彰子,沼辺幸博,鴨井久一,野口和行,渡辺久,石川烈,松山 裕,大橋靖雄,三島昭弘.歯周病治療に用いる臨床パラメータの検査者間信頼性および検査者内信頼性の検討.日本歯周病学会会誌.1999; 41: 144-152.
  58. 菊池方利,松山 裕.疫学からみた血糖コントロールによる糖尿病網膜症抑制.日本眼学紀要.1998; 49: 95-99.
  59. 今村 宏,松山 裕,宮川雄輔,石田公孝,横山隆秀,島田 良,宮川眞一,川崎誠治.小肝癌切除後の残肝再発に対する予後因子の検討.癌臨床・生物統計研究会誌.1998; 24: 18.
  60. 松山 裕.経時観察研究における脱落の統計的問題.Japanese Journal of Biometrics. 1998; 18: 75-84.
  61. 松山 裕.多変量生存時間データに対する解析手法の検討-複数再発と施設間差の解析への応用- .がん治療のあゆみ.1997; 17: 75-81.
  62. 松山 裕,大橋靖雄,手良向聡,坂本純一.施設間差を考慮した生存時間解析.癌の生存時間研究会誌.1997; 17: 63-66.
  63. 松山 裕,大橋靖雄,内野治人,高久史麿,鈴木明.ベスナリノン投与による白血球系障害の市販後調査.薬剤疫学.1996; 1: 33-34.
  64. 松山 裕,林邦彦,佐藤俊哉,大橋靖雄.Generalized Estimating Equationsの理論と応用.薬理と治療.1996;24: 2531-2542.

  1. Kashiwabara K, Matsuyama Y. Point and interval estimation in an efficient adaptive design of flexible sample size determination. At: Joint International Society for Clinical Biostatistics and Australian Statistical Conference 2018, Melbourne, Australia, 26–30 August, 2018. Abstr P4.
  2. Kozuma Ken, Kozuma Kayoko, Shinozaki T, Kashiwabara K, Oba K, Xience PMS Group, PROMUS Element/Element Plus PMS Group, Matsuyama Y. Predictors for angiographic edge restenosis of 2nd generation drug-eluting stents: Integrated angiographic analyses from the post-marketing surveillance studies of everolimus-eluting stents in Japan. ESC Congress 2018, Munich, Germany, August 25-29, 2018
  3. Hagiwara Y, Shinozaki T, Matsuyama Y. G-estimation of structural nested restricted mean time lost models to estimate effect of time-varying treatment on survival outcome. 29th International Biometric Conference. Barcelona, Spain. July 2018. CS41.1.
  4. Kozuma Kayoko, Shinozaki T, Kozuma Ken, Kashiwabara K, Oba K, Aoki J, Awata M, Nanasato M, Shiode N, Tanabe K, Yamaguchi J, Kimura T, Matsuyama Y. Impact of residual stenosis on the angiographic edge restenosis of 2nd generation drug-eluting stents (A quantitative coronary angiography from the post-marketing surveillance studies of cobalt-chromium everolimus-eluting stent in Japan). EuroPCR 2018, Paris, France, May 22-25, 2018
  5. Kashiwabara K, Matsuyama Y. A reasonable adaptive Simon’s two-stage design. At: 38th Annual Conference of the International Society for Clinical Biostatistics, Vigo, Spain, 9–13 July, 2017. Abstr PC2-M29.
  6. Kashiwabara K, Matsuyama Y. An efficient adaptive sample size determination via working sequential designs for confirmatory clinical trials. At: 28th International Biometric Conference, Victoria, Canada, 10–15 July, 2016. Abstr 2465136.
  7. Kashiwabara K, Matsuyama Y. Adaptive group sequential test without predetermination of total and group sample sizes. At: 2014 Joint Statistical Meetings, Boston, MA. August 2–7, 2014. Abstract 312721.
  8. Takeuchi Y, Shinozaki T, Hiramatsu T, Matsuyama Y. The Risk of Liver Injury Associated with Antibiotics Adjusted for Change of Treatments by Inverse Probability of Censoring Weighting (poster presentation). 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Montreal. Aug 2017.
  9. Takeuchi Y, Shinozaki T, Matsuyama Y. Stratified proportional hazards model in self-controlled design: validity and extension of sequential symmetry analysis (poster presentation). Society for Epidemiologic Research 50th Annual Meeting. Seattle. Jun 2017.
  10. Nozaki T, Kashiwabara K, Shinozaki T, Oba K, Matsuyama Y, Ota E, Mori R. A network meta-analysis of prophylactic antibiotics for preventing post-cesarean endometritis. At: The 24th Cochrane Colloquium, Seoul, Korea. October 23–27, 2016.
  11. Hagiwara Y, Shinozaki T, Matsuyama Y. Estimation of modified effectiveness in randomized trials with subsequent treatments using dynamic marginal structural models. UK Causal Inference Meeting 4th annual meeting, London, England, April 13, 2016. P18.
  12. Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Kadoya M, Kaneko S, Ku Y, Kudo M, Takayama T, Nakashima O, The Liver Cancer Study Group of Japan. Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of Liver Cancer Study Group of Japan. 2015 ASCO Annual Meeting, May 29 – June 2, 2015 at the McCormick Place Convention Center in Chicago, Illinois.
  13. Unno M, Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, Honda G, Matsumoto I, Wada K, Furuse J, Furukawa T, Ishida K, Takase K, Matsuyama Y, Nakagawa K, Katayose Y. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus surgery-first for resectable pancreatic carcer (Prep-02/JSAP05). 2015 ASCO Annual Meeting, May 29 – June 2, 2015 at the McCormick Place Convention Center in Chicago, Illinois.
  14. Matsumoto Y, Umemura S, Kobayashi N, Tanaka Y, Sasaki C, Shimizu K, Ogawa A, Kinoshita H, Matsuyama Y, Morita T, Goto K, Ohe Y. Early palliative care for patients with metastatic lung cancer receiving chemotherapy: a feasibility study of a nurse-led screening program. 14th World Congress of the European Association for Palliative Care. 5-8 May 2015, Copenhagen, Denmark.
  15. Shinozaki T, Matsuyama Y. Doubly robust standardization in cohort studies with a binary exposure and censored events. At: 2015 Joint Statistical Meetings, Seattle, WA. Aug 2015. Abstract 316644.
  16. Tajima R, Ohashi Y, Ueshima H, Matsuyama Y. Comparison of Bayesian Regression Methods for Sparse Epidemiologic Data Analysis. Joint Statistical Meeting 2015, Seattle, 10 Aug 2015.
  17. Kawahara T, Matsuyama Y. Doubly Robust Risk Estimation in the Presence of Informative Censoring Incorporating Time-Dependent Covariates. Joint Statistical Meeting 2015, Seattle, 10 Aug 2015.
  18. Kobayashi A, Hasegawa K, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Bandai Y, Teruya M, Yoshimi F, Kawasaki S, Koyama H, Oba M, Takahashi M, Mizunuma N, Matsuyama Y, Watanabe T, Makuuchi M, Kokudo N. A randomized controlled trial evaluating efficacy of adjuvant oral uracil-tegafur (UFT) with leucovorin (LV) after resection of colorectal cancer liver metastases: The UFT/LV study. 50th American Society of Clinical Oncology (ASCO) annual meeting.(abstract 3584). May 30-June 3, 2014, McCormick Place, Chicago, Illinois.
  19. Nakamura M, Muramatsu T, Yokoi H, Okada H, Ochiai M, Suwa S, Matsuyama Y, Nanto S. J-DESsERT 3-Year Outcomes: Largest randomized trial stratified by diabetes mellitus presence, comparing sirolimus and paclitaxel eluting stents. Transcatheter Cardiovascular Therapeutics (TCT). October 27-November 1, 2013, The Moscone Center San Francisco, CA, USA.
  20. Shinozaki T, Matsuyama Y. Robust and efficient estimation of structural nested mean models in randomized trials with partial compliance using generalized method of moments. The XXVIIth International Biometric Conference, Florence, Italy. July 10, 2014. Poster Group 2, Abstract 35.
  21. Shinozaki T, Matsuyama Y, Ohashi Y. "Sensitivity analysis in randomized trials with partial compliance using generalized methods of moments applied to structural nested models" 34th Annual Conference of the International Society for Clinical Biostatistics, Munich, Germany, August 28, 2013. Abstract C34.2.
  22. Yokota I, Matsuyama Y, Ohashi Y. Extension on a landmarking model using a fractional polynomial function for dynamic prediction. 34th Annual Conference of the International Society for Clinical Biostatistics, Munich, Germany, August 25-27, 2013. Abstract P136.
  23. Hideki Kitahara, Katsuhisa Waseda, Kenji Sakamoto, Ryotaro Yamada, Ching-Chang Huang, Daisaku Nakatani, Kenji Sakata, Osami Kawarada, Paul Yock, Yutaka Matsuyama, Hiroyoshi Yokoi, Masato Nakamura, Toshiya Muramatsu, Shinsuke Nanto, Peter Fitzgerald, Yasuhiro Honda. Impact of stent edge plaque burden on lumen preservation after DES implantation: A 3D-IVUS analysis from the J-DESsERT trial. Transcatheter Cardiovascular Therapeutics (TCT) 2012 (October 22-26) in Miami Beach Convention Center, Miami, USA.
  24. Ching-Chang Huang, Hideki Kitahara, Katsuhisa Waseda, Kenji Sakamoto, Ryotaro Yamada, Osami Kawarada, Kenji Sakata, Daisaku Nakatani, Paul Yock, Yutaka Matsuyama, Hiroyoshi Yokoi, Toshiya Muramatsu, Masato Nakamura, Shinsuke Nanto, Peter Fitzgerald, Yasuhiro Honda. Impact of IVUS-detected calcification on subsequent neointimal hyperplasia after drug-eluting stent implantation: An IVUS substudy of the J-DESsERT trial. Transcatheter Cardiovascular Therapeutics (TCT) 2012 (October 22-26) in Miami Beach Convention Center, Miami, USA.
  25. Takao T, Matsuyama Y, Ide T, Yanagisawa H, Kikuchi M, Kawazu S. Relationships of visit-to-visit variability and time-to-effect in systolic blood pressure to the risks of nephropathy and retinopathy in type 2 diabetes. European Association for the Study of Diabetes (EASD) 2012, October 1-5, Berlin, Germany.
  26. Yokota I, Matsuyama Y, Ohashi Y. Comparison of the tests for interval-censored survival data with differential assessment times. XXVIth International Biometrics Conference 2012, Kobe, Japan. August 26 - 31, 2012. Abstract P-3-24.
  27. Sakamaki K, Matsuyama Y, Ohashi Y. Graphical procedures for gatekeeping applications. XXVIth International Biometrics Conference 2012, Kobe, Japan. August 26 - 31, 2012. Abstract P-3-20.
  28. Yoshida M, Matsuyama Y. A stochastic curtailment method based on the widthed log-rank test for delayed treatment effects. XXVIth International Biometrics Conference 2012, Kobe, Japan. August 26 - 31, 2012. Abstract P-3-8.
  29. Shinozaki T, Matsuyama Y, Iimuro S, Ohashi Y, and Ito H. Estimating causal effects of atorvastatin in elderly diabetics. XXVIth International Biometrics Conference 2012, Kobe, Japan. August 26 - 31, 2012. Abstract P-1-24.
  30. Shinozaki T, Matsuyama Y, Iimuro S, Ohashi Y, and Ito H. Estimation of controlled direct effects for dynamic treatment regimes. 2012 Joint Statistical Meetings, San Diego, USA, July 28 - August 2, 2012. Abstract #306152.
  31. Sakamaki K, Matsuyama Y, Ohashi Y. Flexible multiple testing procedures based on resampling methods for gatekeeping applications. 2012 Joint Statistical Meetings, San Diego, USA, July 28 - August 2, 2012. Abstract #306148.
  32. Yokota I, Matsuyama Y, Ohashi Y. Simulation studies on the analysis of interval-censored survival data with differential assessment times. 2012 Joint Statistical Meetings, San Diego, USA, July 28 - August 2, 2012. Abstract #305521.
  33. Yoshida M, Matsuyama Y. A group sequential method based on the widthed log-rank test for delayed treatment effects. 2012 Joint Statistical Meetings, San Diego, USA, July 28 - August 2, 2012. Abstract #304784.
  34. Taguri M, Matsuyama Y, Ohashi Y. Doubly robust estimation of the generalized impact fraction. East Asia Regional Biometric Conference 2012. February 2-3, 2012, Seoul National University Hoam Convention Center, Seoul, Korea.
  35. Saiura A, Ueno H, Kosuge T, Matsuyama Y, Ishii H, Nakao A, Doi R, Tanaka M. A phase II trial of gemcitabine and S-1 therapy in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy for pancreatic cancer (JSAP-03). ASCO 2012 Gastrointestinal Cancers Symposium (January 19 - 21, 2012). Abstract #88144
  36. Ng CFS, Matsuyama Y, Ohashi, Y. Relative incidence of adverse events in disseminated intravascular coagulation patients using modified self-controlled case series method. The 32nd annual Conference of the International Society for Clinical Biostatistics (ISCB). August 21-25 in Ottawa, Canada. Abstract C134.
  37. Shinozaki T, Matsuyama Y, Ohashi Y. Estimating controlled direct effects for time-varying treatments using structural nested mean models. 2011 Joint Statistical Meetings, Miami, USA, August 1 - August 5, 2011. Abstract 360.
  38. Matsuyama Y. A comparison of the results of intent-to-treat, per-protocol, and g-estimation in the presence of nonrandom treatment changes in a time-to-event non-inferiority trial. 2010 Joint Statistical Meetings, Vancouver, Canada, August 1 - August 5, 2010. Abstract 501.
  39. Takeuchi A, Matsuyama Y, Nitta H, Ono M. Adjustment of regional differences using generalized additive mixed model to estimate the health effect of PM2.5. 2010 Joint Statistical Meetings, Vancouver, Canada, August 1 - August 5, 2010. Abstract 530.
  40. Taguri M, Matsuyama Y, Ohashi Y. Model selection for causal parameters in structural mean models based on a quasi-likelihood. 2010 Joint Statistical Meetings, Vancouver, Canada, August 1 - August 5, 2010. Abstract 360.
  41. Yoshida M and Matsuyama Y. A stochastic curtailment method based on the widthed log-rank test for delayed treatment effects. The 31h annual Conference of the International Society for Clinical Biostatistics (ISCB). 29July-2August 2010, Montpellier, France. Abstract P1-2715.
  42. Isayama H, Yasuda I, Ryozawa S, Maguchi H, Igarashi Y, Matsuyama Y, Katanuma A, Hasebe O, Irisawa A, Itoi T, Mukai H, Arisaka Y, Okushima K, Uno K, Kida M, Tamada K. The result of Japanese multicenter randomized trial of endoscopic stenting for the non-resection pancreatic head cancer. American Society for Gastrointestinal Endoscopy. McCormick Place in Chicago, IL, May 30 - June 4, 2009
  43. Taguri M, Matsuyama Y, Ohtsu H, Harada A, Ohashi Y, Ueshima H. Stroke incidence attributable to metabolic risk factors stratified by obesity: Using doubly robust estimators of the population attributable fraction. The XVIII IEA World Congress of Epidemiology, Porto Alegre, Brazil, 20/September-24/September, 2008
  44. Takeuchi A, Matsuyama Y, Omori T, Ono M, and Nitta H. Effects of ambient air pollution (PM2.5) on daily mortality in Japanese 20 cities. The XXIVth International Biometric Conference, Dublin, Ireland, 13/July-15/July, 2008
  45. Yanaihara H, Deguchi N, Fuji K, Yasunaga H, Matsuyama Y, and Ohe K. Influence of hospital and surgeon volume on operative time, blood loss, and perioperative complications in radical nephrectomy: The results from nationwide survey in Japan. American Urological Association Annual Meeting. Journal of Urology 179(4) Supplement: 29, 2008 Orlando, Florida 17-22 May 2008
  46. Kosuge T, Ueno H, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, and Tanaka M. A randomized phase III study comparing gemcitabine monotherapy with observation in patients with resected pancreatic cancer. The 14th European Cancer Conference. 23September-27September 2007, Barcelona, Spain.
  47. Sugihara M, Matsuyama Y, Matsushita Y, and Orihashi Y. Estimation of causal effects using IPTW methods based on time-dependent propensity score for survival data. The 28th annual Conference of the International Society for Clinical Biostatistics (ISCB). 29July-2August 2007, Alexandroupolis, Greece.
  48. Tanaka S, Matsuyama Y, and Ohashi Y. Estimating surrogate endpoints defined by principal causal effects. 2007 Joint Statistical Meetings, Salt Lake City, Utha, July 29 - August 2, 2007. Abstract 123.
  49. Tanaka S, Tanaka S, Matsuyama Y, and Yamamoto S. Inverse probability widthed estimators in the stratified nested case-control sampling method. 2007 Joint Statistical Meetings, Salt Lake City, Utha, July 29 - August 2, 2007. Abstract 220.
  50. Uemura K, Matsuyama Y, and Ohashi Y. Sample size re-calculation methods in clinical trials based on the observed treatment difference at an interim look. XXIIIrd International Biometrics Conference. Montreal, Canada, 17/July-21/July, 2006.
  51. Tanaka Y, Matsuyama Y, Ohashi Y and MEGA Study group. Estimation of treatment effect adjusting for non-compliance using the intensity score method - an application to a large primary prevention study for coronary events -. XXIIIrd International Biometrics Conference. Montreal, Canada, 17/July-21/July, 2006.
  52. Morita S and Matsuyama Y. Estimation of the average causal effect among subgroups defined by posttreatment variables. The 25th annual Conference of the International Society for Clinical Biostatistics (ISCB). 15- 19, August, 2004, Leiden, The Netherlands. Cont. 2003: 24(3S), 56S.
  53. Teramukai S, Matsuyama Y and Mizuno S. Exploring between study heterogeneity in individual patient data meta-analysis. The 3rd joint meeting of the International Society for Clinical Biostatistics (ISCB) and Society for Clinical Trials (SCT). London, UK. 20th-24th, July, 2003 Controlled Clinical Trials. 2003: 24(3S), 112S.
  54. Matsuyama Y and Yamaguchi Y. Estimation of the marginal survival time in the presence of competing risks. The 3rd joint meeting of the International Society for Clinical Biostatistics (ISCB) and Society for Clinical Trials (SCT). London, UK. 20th-24th, July, 2003 Controlled Clinical Trials. 2003: 24(3S), 56S.
  55. Kikuchi M, Matsuyama Y, and Ide T. The cause and effect relationship between pancreatic ?-cell impairment or insulin resistance and the natural history of development of type 2 diabetes in the employees of a trade firm in Tokyo. 8th Annual Meeting of the European Association for the Study of Diabetes. Budapest, Hungary, 1-5/September, 2002
  56. Matsuyama Y. Sensitivity analysis for the estimation of rates of change with non-ignorable drop-out: An application to a randomized clinical trial of the vitamin D3. XXIst International Biometrics Conference. Freiburg, Germany, 21/July-26/July, 2002 Proceedings. 2002:132.
  57. Sato T and Matsuyama Y. Marginal structural models as a tool for standardization. XXIst International Biometrics Conference. Freiburg, Germany, 21/July-26/July, 2002 Proceedings. 2002:29.

学会発表(国内)

  1. 細井宏輝, 竹内由則, 柏原康佑, 今井博久, 松山裕. 国民健康保険加入者における特定保健指導受診の継続的な効果の検証. 第29回日本疫学会学術総会. 東京都. 2019年1-2月.
  2. 萩原康博,福田武蔵,松山裕.Modified Least-Squares回帰による妥当なリスク差推定に必要な1交絡変数当たりのイベント数.2018年度日本計量生物学会年会,東京,2018/3/30.
  3. 竹内由則, 篠崎智大, 隈丸拓, 平松達雄, 松山裕. 薬剤疫学研究におけるIntent-to-treat effectとPer-protocol effect: 抗菌薬による肝障害発症リスク評価への適用事例. 日本薬剤疫学会第23回学術総会. 東京都. 2017年11月.
  4. 村上義孝, 上原里程, 柏原康佑, 松山裕. 受療行動調査における患者満足度・医師からの説明理解度の相互関連性. At: 第75回日本公衆衛生学会総会, 大阪, 日本. October 26–28, 2015. 抄録集 p.363.
  5. 柏原康佑, 松山裕. 症例集積完遂が困難な進行中ランダム化比較試験における条件付き検出力に基づく逐次デザインを利用した症例数再設計法. At: 2017年度日本計量生物学会年会, 東京, 日本. Mar 16–17, 2017. 講演予稿集 pp.1–6.
  6. 竹内由則, 篠崎智大, 松山裕. 疫学研究における自己対照研究手法による推定値の比較: シミュレーション研究. 日本薬剤疫学会第22回学術総会. 京都市. 2016年11月.
  7. 篠崎 智大,松山 裕.ペアワイズ層別Coxモデルによるoverall Cの推測.2016年度統計関連学会連合大会,金沢,2016年9月.
  8. 上妻 佳代子, 上妻 謙, 松山 裕. 定量的冠動脈造影法(QCA)の計測用ソフトウエアQAngio XAにおけるバージョン間の一致度に関する検討. 第25回日本心血管インターベンション治療学会, 東京, 2016/7/7-9.
  9. 降旗 啓, 松山 裕. 治療中止による脱落をともなうランダム化臨床試験データの解析:Controlled Imputation アプローチの性能評価. 2016年度計量生物学会. 東京. 2016年3月.
  10. 小西 宏,伊藤真理,松山 裕.全国自治体の妊婦健康診査における子宮頸がん検診の実施状況調査.第74回日本公衆衛生学会.長崎 2015/11/04-11/06
  11. 伊藤真理,小西 宏,有藤亜希子,岩成 治,大橋靖雄,松山 裕.子宮頸がん住民検診未受診者層への自己採取HPV検査導入トライアル(島根県出雲市).第74回日本公衆衛生学会.長崎 2015/11/04-11/06
  12. 上原里程, 村上義孝, 柏原康佑, 松山裕. 受療行動調査を用いた在宅医療と医療施設特性との関連分析. At: 第74回日本公衆衛生学会総会, 長崎, 日本. November 4–6, 2015. 抄録集 p.382.
  13. 横田 勲,松山 裕.動的予測を用いた代替エンドポイントの評価.2015年度日本計量生物学会年会, 京都, 2015/3/12-13. 35-37.
  14. 福田武蔵,松山 裕.中間解析をともなうmarker stratified designの提案とその特性評価.2015年度日本計量生物学会年会, 京都, 2015/3/12-13. 39-44.
  15. 奥井 佑,松山 裕.構造ネスト加速モデルを用いたがん臨床試験における後治療の影響評価.2015年度日本計量生物学会年会, 京都, 2015/3/12-13. 69-74.
  16. 村上義孝, 松山裕, 宮下光令, 上原里程, 柏原康佑. 厚生労働省受療行動調査による患者満足度に影響を与える医療施設特性の探索. At: 第73回日本公衆衛生学会総会, 栃木, 日本. November 5–7, 2014. 抄録集 p.323.
  17. 萩原康博,木原清敬,松山裕,大橋靖雄.質調整生存時間の効用値欠測と生存時間打ち切りに対する感度解析:進行膵癌臨床試験データへの適用.2014年度日本計量生物学会年会,東京,2014/5/24.
  18. 和泉志津恵,松山 裕,浜田知久馬.大学の医歯薬学分野(看護学を含む)における統計教育の参照基準の改訂案の作成. 2013年度 統計関連学会連合大会.大阪.2013/9/9.
  19. 高本幹大,篠崎智大,松山裕,大橋靖雄.長期毒性を考慮した抗悪性腫瘍薬の用量設定試験デザイン.2013年度日本計量生物学会年会, 福島, 2013/5/24.
  20. 川原拓也, 松山裕, 大橋靖雄. 採取済み検体を用いたケース・コントロール研究における逐次検定手法の比較. 2013年度日本計量生物学会年会, 福島, 2013/5/24.
  21. 松山 裕.臨 床・疫学データにおける平均因果効果の推定-実際の応用例の紹介-.2010年度 統計関連学会連合大会.東京.2010/09/08
  22. 高尾淑子,井出健彦,柳澤裕 之,菊池方利,河津捷二,松山裕.2型糖尿病患者における網膜症発症,進展への空腹時血糖の変動と年齢の影響:長期追跡研究.第53回日本糖尿病学会.岡山.5月27日(木)-29日2010.
  23. 小菅智男, 上野秀樹, 松山裕, 山本順司, 中尾昭公, 江川新一, 土井隆一郎, 羽鳥隆, 門田守人, 田中雅夫.膵癌に対して行うべき集学的治療 ゲムシタビンを用いた補助化学療法.日本癌治療学会誌42巻2号 Page266 2007
  24. 砂原和仁,福田敬,松山裕,金澤康徳,小林秀資,高塚志保,寺阪ユキ,池田知成.コレステロール高値者への生活習慣改善プログラムの効果~職域でのランダム化比較試験.第66回日本公衆衛生学会総会 愛媛松山 講演報告集.2007;
  25. 田栗 正隆,松山 裕,大橋 靖雄.共変量の測定誤差を考慮した階層的回帰モデルによる食事データの解析 糖尿病合併症に対する大規模臨床試験(JDC Study)への適用.2007年度 統計関連学会連合大会 講演報告集.2007; 7.
  26. 吉田征太郎,松山 裕,上島弘嗣,大橋靖雄.マルコフ連鎖モンテカルロ法によるリスク因子の効果と地域効果の交互作用の解析-日本動脈硬化縦断研究(JALS)0次統合研究データへの適用-.2006年度 第17回日本疫学会学術総会.第17回日本疫学会学術総会講演集.103.
  27. 吉田瑞樹,松山 裕,大橋靖雄.IPCW法を用いたdependent drop-outの影響を補正した治療効果の推定 - 冠動脈イベントに対する大規模一次予防試験(MEGA Study)データへの適用-.2006年度 統計関連学会連合大会.講演報告集.2006;184.
  28. 金子徹治,松山 裕,大橋靖雄.既存治療法の選択を目的とした臨床試験デザインの検討.2006年度 統計関連学会連合大会.講演報告集.2006;266.
  29. 斉藤真梨,松山 裕,大橋靖雄.発達度データにおけるGibbs samplingを用いた項目反応モデルパラメータの推定.2006年度 統計関連学会連合大会.講演報告集.2006;105.
  30. 竹内文乃,松山 裕,大橋靖雄.Monte Carlo Risk Analysis法による疫学研究結果が含む複数の不確実性の考慮.講演報告集.2006年度 統計関連学会連合大会.2006;258.
  31. 上村鋼平,松山 裕,大橋靖雄.中間評価で観察された群間差に基づく症例数再設計方法の検討.2006年度 統計関連学会連合大会.講演報告集.2006;135.
  32. 田中夕香理,松山 裕,大橋靖雄.Intensity score法によるノンコンプライアンスの影響を補正した治療効果の推定 ? 冠動脈イベントに対する大規模一次予防試験(MEGA Study)データへの適用-.講演報告集.2006年度 統計関連学会連合大会.2006;185.
  33. 田中司朗,松山 裕,大橋靖雄.骨粗鬆症治療薬の骨折発生抑制効果に関する構造平均モデルを用いた推定.2005年度 統計関連学会連合大会.講演報告集.2005;261-262.
  34. 千葉康敬,松山 裕,佐藤俊哉.未観察交絡要因に対する周辺平均推定による感度解析.2005年度 統計関連学会連合大会.講演報告集.2005; 263.
  35. 坂本公彦,松山 裕,大橋靖雄.メタアナリシスにおける公表バイアスに対するベイズ的な感度解析.2005年度 統計関連学会連合大会.講演報告集.2005;219-220.
  36. 今村宏, 長谷川潔, 伊地知正賢, 松山 裕, 菅原寧彦, 佐野圭二, 國土典宏, 幕内雅敏.ミラノ基準の再検討.第40回日本移植学会総会.移植.2004; 39(6): 702.
  37. 建石良介,吉田晴彦,峯規雄,松山 裕,小俣政男.肝細胞癌における3種の腫瘍マーカーの診断能についてのメタアナリシス. 第40回日本肝臓学会総会講演要旨集.2004; P021.
  38. 土居主尚,松山 裕,大橋靖雄.死亡と脱落を考慮したQOLデータの解析.2004年度 統計関連学会連合大会.講演報告集.2004;253-254.
  39. 水野佐智子,松山 裕,大橋靖雄.Frailty modelsにおける予測の精度に関する検討.2004年度 統計関連学会連合大会.講演報告集.2004;135-136.
  40. 高山忠利,幕内雅敏,國土典宏,今村宏,松山 裕,川崎誠治,須郷広之,有井滋樹,寺本研一,加藤高明,猪飼伊和夫,山岡義生.外科治療についてのエビデンスの推奨.第40回日本肝癌研究会 2004.講演抄録集.2004: 49.
  41. 鍵村達夫,松山 裕,佐藤俊哉.海外で実施された試験結果の国内患者集団への外挿可能性の検討.2003年度 統計関連学会連合大会.
  42. 千葉康敬,松山 裕,佐藤俊哉.Alloyed gold standard を用いた誤分類の調整法.2003年度日本計量生物学会シンポジウム.講演予稿集.2003; 13-18.
  43. 菊池方利,松山 裕,井出健彦.一商社の34年間の健康診断データによる糖尿病発症とインスリン抵抗性と?細胞障害の自然歴.第46回日本糖尿病学会年次学術集会.2003/5/22-24
  44. 手良向 聡,松山 裕.研究間の異質性を考慮したメタアナリシス.第13回日本疫学会学術総会.日本疫学会学術総会講演集.2002; 138.
  45. 千葉康敬,松山 裕,佐藤俊哉.DAGに基づく誤分類と測定誤差の解釈.2002年度統計関連学会連合大会.講演予稿集.2002; 310-311.
  46. 川戸美由紀,橋本修二,山口拓洋,中村好一,木村博和,市川誠一,松山 裕,木原正博,白阪琢磨.拠点病院におけるHIV/AIDS受療者数の推移.第16回(2002年)日本エイズ学会学術集会・総会.抄録集.2002: 403.
  47. 松山 裕,川戸美由紀,山口拓洋,梅田珠実,城所敏英,市川誠一,橋本修二.日本国籍者のHIV/AIDSの特徴-サーベイランスによる先進諸国との比較-.第16回(2002年)日本エイズ学会学術集会・総会.抄録集.2002: 404.
  48. 千葉康敬,松山 裕,佐藤俊哉,吉村功.等分散が仮定できない測定誤差モデルにおける推定法のシミュレーションによる検討.2002年度日本計量生物学会シンポジウム.講演予稿集.2002:61-66.
  49. 嘉田晃子,松山 裕,佐藤 俊哉.中止・脱落の理由を考慮したIPCW法による臨床試験データの解析.2002年度日本計量生物学会シンポジウム.講演予稿集.2002:55-60.
  50. 小川幸男,松山 裕,佐藤 俊哉.欠測が中間変数に依存する場合のmultiple imputationによる解析と欠測のある対象者を除いた解析のシミュレーションによる比較.2002年度日本計量生物学会シンポジウム.講演予稿集.2002:49-54.
  51. 佐藤俊哉、松山 裕.多変量で調整したSMR.第12回(2001年)日本疫学会学術総会.第12回日本疫学会学術総会講演集.2001:159.
  52. 松山 裕.IPCW法によるランダムでない欠測データに対する感度解析.2001年度日本計量生物学会・応用統計学会合同年次大会.特別セッション:欠測値や外れ値を含むデータの統計解析法.抄録集.2001:157-164.
  53. 小川幸男,松山 裕,佐藤俊哉.Complete case解析とMultiple imputationの比較.2001年度日本計量生物学会・応用統計学会合同年次大会.抄録集.2001:133-138.
  54. 佐藤俊哉,松山 裕.治療を繰り返し実施した場合のランダム化にもとづく因果効果の推定.2001年度日本計量生物学会・応用統計学会合同年次大会.抄録集.2001:79-82.
  55. 沼部幸博,長内麻子,清信浩一,神田姜姫,斉藤洋一,松村彰子,鴨井久一,野口和行,渡辺 久,石川 烈,松山 裕,大橋靖雄,三島昭宏.歯周病診断キット(PTMキット)の臨床応用-診断および再評価-.第43回日本歯周病学会秋季学術大会.日本歯周病学会会誌.2000:42:137.
  56. 渡辺 久,野口和行,石川 烈,長内麻子,沼部幸博,鴨井久一,松山 裕,大橋靖雄,三島昭宏.歯周病診断キット(PTMキット)の臨床応用-治療計画への活用-.第43回日本歯周病学会秋季学術大会.日本歯周病学会会誌.2000:42:136.
  57. 三島昭宏,長内麻子,沼部幸博,鴨井久一,野口和行,渡辺 久,石川 烈,松山 裕,大橋靖雄.歯周病診断キット(PTMキット)の臨床応用-AST量から見たブラッシング効果-.第43回春季日本歯周病学会.日本歯周病学会会誌.2000:42:140.
  58. 沼部幸博,長内麻子,清信浩一,神田姜姫,斉藤洋一,松村彰子,鴨井久一,野口和行,渡辺 久,石川 烈,松山 裕,大橋靖雄,三島昭宏.歯周病診断キット(PTMキット)の臨床応用-治療効果のモニタリング-.第43回春季日本歯周病学会.日本歯周病学会会誌.2000:42: 90.
  59. 沼部幸博,清信浩一,長内麻子,東 綾美,神田善姫,斎藤洋一,松村彰子,鴨井久一,野口和行,渡辺 久,石川 烈,松山 裕,大橋靖雄,三島昭宏.Periodontal Tissue Monitor(PTM)キットの歯周病診断への有用性について.第1回(1999年)日本歯科人間ドック学会学術大会.
  60. 吉村健一,森田智視,岸本淳司,松山 裕,大橋靖雄.QOL調査票における因子構造不変性の検討-多母集団同時分析の適用-.1999年度日本計量生物学会・応用統計学会合同年次大会.抄録集.1999:61-64.
  61. 鎌倉光宏,梅田珠実,山本太郎,木原正博,松山 裕,橋本修二,市川誠一,中村好一,城所敏英,木村哲.The analysis of recent status and trends of AIDS/HIV in the world. 第12回日本エイズ学会総会.抄録集.1998:199.
  62. 松山 裕,橋本修二,市川誠一,中村好一,城所敏英,梅田珠実,鎌倉光宏,木村哲,木原正博.エイズサーベイランス報告に基づくHIV感染者,AIDS患者報告数の推移傾向.第12回日本エイズ学会総会.抄録集.1998:205.
  63. 渡辺 久,野口和行,杉山栄一,穐山文彦,荒蒔まや,萩原さつき,石川烈,長内麻子,沼辺幸博,鴨井久一,松山 裕,大橋靖雄,三島昭弘.歯周病診断キット(PTM)の臨床応用―予診時および精密検査時の横断的研究―.第41回日本歯周病学会.抄録集.1998:70.
  64. 長内麻子,松村彰子,斎藤洋一,東綾実,神田善姫,沼辺幸博,鴨井久一,野口和行,渡辺久,石川烈,松山 裕,大橋靖雄,三島昭弘.歯周病診断キット(PTM)の臨床応用―24週までの長期経過観察―.第41回日本歯周病学会.抄録集.1998:71.
  65. 今村 宏,松山 裕,宮川雄輔,石田公孝,横山隆秀,島田 良,宮川眞一,川崎誠治.小肝癌切除後の残肝再発に対する予後因子の検討.第19回癌の生存時間研究会.プログラム抄録集.1997: 13.
  66. 松山 裕,大橋靖雄,手良向聡,坂本純一.施設間差を考慮した生存時間解析.第18回癌の生存時間研究会.プログラム抄録集.1996: 23.
  67. 松山 裕,大橋靖雄.Gibbs samplerによる多施設癌臨床試験の統計解析.第64回日本統計学会.講演要旨集.1996: 37-38.
  68. 松山 裕,大橋靖雄.経時臨床データに対する混合モデルの応用と投与量の適応的変更法.統計科学合同研究集会予稿集(1994年度計量生物学会).1994: 108-109.

  1. Shinozaki T, Matsuyama Y. (November 2014). “Doubly robust estimation of a marginal structural model in the exposed population.” At: Kyoto International Conference on Modern Statistics in the 21st Century, Kyoto, Japan. Chair: Manabu Iwasaki. (Invited)
  2. Matsuyama Y. Semiparametric estimation of treatment effect in a randomized clinical trial with missing data. International Symposium Incomplete Data Analysis and Causal Inference, Osaka University, 22-23 September 2013.
  3. Matsuyama Y and Tanaka Y. Estimation of treatment effect adjusting for non-compliance using the intensity score method. 科学研究費補助金(基盤研究 (A) (1))シンポジウム「不完全データ解析とその周辺」 東京.2006/1/23.

シンポジウム(国内)

  1. 松山 裕.臨床研究のデザイン:生物統計学の立場から.第50回糖尿病学の進歩.東京.2016/2/19
  2. 松山 裕.臨床研究のデザインと統計解析.第21回スパインフロンティア.埼玉.2016/2/13
  3. 松山 裕.臨床研究のデザインと統計解析.臨床統計セミナー.島根大学医学部.2015/10/23
  4. 松山 裕.臨床研究のスタディーデザイン:生物統計学の立場から.第38回日本高血圧学会総会シンポジウム13.愛媛.2015/10/11
  5. 松山 裕.縦断データの統計解析.東京都健康長寿医療センター研究所.2013/12/02
  6. 松山 裕.生物統計学入門.平成25年度 国公私立大学病院医療技術関係職員研修.東京大学医学部附属病院.2013/10/03
  7. 松山 裕,篠崎智大.経時的な測定値を用いたイベントリスク評価.2012年度公益信託日本動脈硬化予防研究基金統合研究 統計解析チュートリアル.東京.2012/10/13
  8. 松山 裕.競合リスクを考慮した疾患発症リスクの推定.2011年度公益信託日本動脈硬化予防研究基金統合研究 統計解析チュートリアル.東京.2011/09/30
  9. 松山 裕.相関のあるデータの解析方法.2010年度公益信託 日本動脈硬化予防研究基金統合研究 統計解析チュートリアル.東京.2010/09/10
  10. 松山 裕.観察研究データの統 計解析- overview -.SAS Learning Session 2010: SAS Forum ユーザー会学術総会2010 東 京 2010/7/28
  11. 松山 裕.ゲートキーピング法による多重性の調整.BioS20周年記念:特別セミナー.東京 2010/3/20
  12. 松山 裕.統計家からみたプロトコル作成の留意点.癌化学療法講演会.東京.2008/4/3.
  13. 松山 裕.Propensity Scoreの概念と実例.第17回YCC (Yokohama Circulation Club).横浜.2008/2/29.
  14. 松山 裕.臨床試験の方法論について.タキソール10周年記念肺がん学術講演会.札幌.2007/10/20.
  15. 松山 裕.がん臨床試験における統計解析の基礎.九州肺癌治療セミナー.福岡.2007/7/21.
  16. 松山 裕.がん臨床試験におけるデザインと統計解析.西日本胸部腫瘍臨床研究機構(WJTOG)臨床試験セミナー.大阪.2006/11/25.
  17. 松山 裕.GLIMMIXプロシジャの紹介.SAS Learning Session 2006: SAS Forum ユーザー会 学術総会2006. SAS Institute Inc.2006/7/29
  18. 松山 裕.疫学研究の必要性と可能性.AstraZeneca Symposium on Molecular Targeted Therapy in NSCLC 2006. 東京.16Sep2006.
  19. 田中司朗,松山 裕.PROC GAMの紹介.SAS医薬・統計ワーキンググループ ユーザ会学術総会.東京大学.2006/5/31
  20. 松山 裕.特別講演:Observational Study v.s. RCTについて.第106回日本外科学会定期学術集会.東京国際フォーラム.2006/3/31
  21. 松山 裕.ベイズ統計学入門.SAS Learning Session 2005: SAS Forum ユーザー会 学術総会2005.SAS Institute Inc.2005/7/30
  22. 松山 裕.科学的根拠に基づいた診療ガイドラインについて.第40回日本肝癌研究会シンポジウム「科学的根拠に基づいた肝癌の診療と治療」基調講演.2005.
  23. 松山 裕.臨床研究における試験統計家の役割.癌化学療法研究会.東京.2005/3/29
  24. 松山 裕.臨床試験の統計解析.臨床研究支援特別講座「臨床試験のあり方を考える」.大阪.2004/10/27.
  25. 松山 裕.NLMIXEDプロシジャの紹介.SAS Learning Session 2004: SAS Forum ユーザー会 学術総会2004.東京カンファレンスセンター品川.2004/7/31
  26. 森田智視,松山 裕.ランダム化比較試験における治療開始後変数で定義されるサブグループ間での平均因果効果の推定.SAS Forum ユーザー会 学術総会2004.講演予稿集.2004; 51-61.
  27. 松山 裕.Propensity Scoreを用いた交絡調整.2003年度統計関連学会連合大会 チュートリアルセミナー.名城大学.
  28. 佐藤俊哉,松山 裕.疫学・臨床研究における因果推論.2003年度日本計量生物学会チュートリアルセミナー.
  29. 松山 裕,山口拓洋.競合リスクが存在する場合の周辺生存関数の推定.文部科学省科学研究費補助金「因果推論のための統計モデルとその推測法(代表者 宮川雅巳)」.京都大学.2003/3/4.
  30. 松山 裕.観察研究におけるUnmeasured confoundersに対する感度解析.文部科学省科学研究費補助金「因果推論のための統計モデルとその推測法(代表者 宮川雅巳)」.統計数理研究所.2002/8/23.
  31. 佐藤俊哉,松山 裕.標準化のツールとしての周辺構造モデル.文部科学省科学研究費補助金「因果推論のための統計モデルとその推測法(代表者 宮川雅巳)」.統計数理研究所.2002/8/23.
  32. 松山 裕.臨床試験を支える因果推論:反事実因果モデルと因果効果の推定.第69回(2001年)統計学会チュートリアルセミナー.第69回日本統計学会チュートリアルセミナー.予稿集.2001: 11-26.
  33. 松山 裕.IPCW法によるnon-ignorable drop-outに対する感度解析.文部科学省科学研究費補助金「因果推論のための統計モデルとその推測法(代表者 宮川雅巳)」.京都大学.2001.
  34. 松山 裕.Non-complianceをともなう二値経時観察データに対するランダム化にもとづく解析.平成12年度 文部省科学研究費シンポジウム.基盤研究(A)(1)「統計学における理論と応用の総合的研究」(Statistical Issues in Biomedical Research and Drug Development).2001, 3/8,9. 要旨集23-30.
  35. 松山 裕.経時観察データの解析.東京都老人総合研究所.25/06/1999.
  36. 松山 裕,大橋靖雄.ベイズ流統計手法の理論と応用-医学研究への応用-.第64回日本統計学会チュートリアルセミナー.予稿集.1996: 32-41.
  37. 松山 裕.施設間差を考慮した生存時間解析.日本医療情報学会医学知識・診断論理研究会,生存時間分析の最新の展開.平成8年度第1回日本医療情報学会医学知識・診断論理研究会抄録集.1996: 59-72.
  38. 松山 裕.経時観察研究における脱落の統計的問題.第3回計量生物セミナー.
  39. 松山 裕,大橋靖雄.Gibbs samplerによる多施設癌臨床試験の統計解析.1996年度数学会統計数学分科会.複雑非線型現象の「離散・ノンパラ・セミパラ」解析の研究.
  40. 松山 裕.Generalized Estimating Equationsの理論と応用.統計学シンポジウム.広島大学原爆放射能医学研究所.1995/11/24.
  41. 松山 裕.投与量の適応的制御とその臨床試験への応用.第13回薬効評価研究会.
  42. 松山 裕,林邦彦,佐藤俊哉,山本精一郎,大橋靖雄.Generalized Estimating Equationsの理論と応用.第63回日本統計学会チュートリアルセミナー.予稿集.1995: 2-16.

  1. Shinozaki T, Matsuyama Y. Data analysis on real world data: an overview. In: Sudoh, O. (editor). Epidemiologic Research on Real World Medical Data in Japan. Switzerland: Springer International Publishing, 2019 (forthcoming).

TOP